Carbutamide

271.335

271.34

206-424-4

E3K8P4869P

246862|242409

DTXSID8022741

C83597

Crystals

A - Alimentary tract and metabolism

2935009090

110

1.01

1.266g/cm3

144-145 °C

1.564

In water, 535 mg/l @ 37 deg C

Oral-rat LD50: 4400 mg/kg; Oral-Mouse LD50: 250 mg/kg

Thermal decomposition emits toxic nitrogen oxides and sulfur oxide fumes

Treasury is ventilated, low temperature and dry; stored separately from food materials

P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, P501

H315

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

highly toxic

...SODIUM CARBONATE REDUCED...DRUG'S TERATOGENIC & LETHAL ACTION IN RAT.|DRUGS THAT MAY INCR RISK OF HYPOGLYCEMIA FROM SULFONYLUREAS INCL OTHER HYPOGLYCEMIC AGENTS, SULFONAMIDES, PROPRANOLOL, SALICYLATES, CLOFIBRATE, PHENYLBUTAZONE, PROBENECID, DICUMAROL, CHLORAMPHENICOL, MONOAMINE OXIDASE INHIBITORS, & ALCOHOL. /SULFONYLUREAS/|ALCOHOL & SALICYLATES BECAUSE OF THEIR DIRECT HYPOGLYCEMIC ACTION, MAY PRECIPITATE HYPOGLYCEMIC COMA IN PT RECEIVING SULFONYLUREAS. ... PROPRANOLOL, BY INTERFERING WITH GLYCOGENOLYSIS & GLUCAGON RELEASE, ENHANCES THE HYPOGLYCEMIC ACTION OF SULFONYLUREAS. /SULFONYLUREAS/|THE SULFONYLUREA-MEDIATED SECRETION OF INSULIN CAN BE MODIFIED BY CONCOMITANT PERFUSION OF SECOND DRUG THAT DISPLACES SULFONYLUREA IN PANCREAS. THUS, THE DRUG INTERACTION AT THE TARGET ORGAN OR RECEPTOR SITE SHOULD BE UNDERSTOOD TO PROVIDE ADEQUATE DRUG THERAPY.|For more Interactions (Complete) data for 1-BUTYL-3-SULFANILYLUREA (8 total), please visit the HSDB record page.

Hypoglycemic Agents|MEDICATION (VET): CARBUTAMIDE HAD A SIGNIFICANT ANTITHYROID EFFECT IN RATS WHEN ADDED TO THEIR DIETS FOR 10-14 DAYS. IT REDUCED THYROID (131)-IODINE UPTAKE & REDUCED SYNTHESIS OF THYROXINE.|CARBUTAMIDE.../IS/ A SULFANILAMIDE ORAL HYPOGLYCEMIC DRUG USED IN DIABETES...|THE SULFONYLUREAS SHOULD BE USED ONLY IN PATIENTS WITH DIABETES OF THE INSULIN-INDEPENDENT TYPE WHO CANNOT BE TREATED WITH DIET ALONE. /SULFONYLUREAS/|HYPOGLYCEMIC AGENT

HEMATOLOGICAL (LEUKOPENIA, AGRANULOCYTOSIS, THROMBOCYTOPENIA, PANCYTOPENIA, & HEMOLYTIC ANEMIA), CUTANEOUS (RASHES, PHOTOSENSITIVITY), GI (NAUSEA, VOMITING, RARELY HEMORRHAGE), & HEPATIC (INCR SERUM ALKALINE PHOSPHATASE, CHOLESTATIC JAUNDICE) REACTIONS HAVE BEEN REPORTED. /SULFAMYLUREA/|THE INCREASE IN CARDIOVASCULAR MORTALITY DURING TREATMENT WITH SULFONYLUREAS...IS THE MAJOR TOXIC EFFECT SO FAR REPORTED. /SULFONYLUREAS/|SULFONYLUREAS SHOULD NOT BE USED IN PATIENTS WITH HEPATIC OR RENAL INSUFFICIENCY BECAUSE OF THE IMPORTANT ROLE OF THE LIVER IN THEIR METABOLISM & OF KIDNEY IN EXCRETION OF THE DRUGS & THEIR METABOLITES. INTOLERANCE TO ALCOHOL...OCCURS OCCASIONALLY IN PT TAKING SULFONYLUREAS. /SULFONYLUREAS/|THESE AGENTS ARE...NOT RECOMMENDED FOR USE IN PREGNANCY... TERATOGENESIS IN ANIMALS HAS BEEN OBSERVED TO FOLLOW THE ADMIN OF LARGE DOSES. /SULFONYLUREAS/|For more Drug Warnings (Complete) data for 1-BUTYL-3-SULFANILYLUREA (7 total), please visit the HSDB record page.

Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)

THE SULFONYLUREAS ARE READILY ABSORBED FROM THE GI TRACT. THE MOST IMPORTANT DIFFERENCE AMONG THE SULFONYLUREAS, FOR CLINICAL PURPOSE, IS IN THEIR DURATION OF ACTION... /SULFONYLUREAS/_|SULFONYLUREAS ARE LARGELY BOUND TO PLASMA PROTEINS & ARE DISTRIBUTED IN THE EXTRACELLULAR SPACE. /SULFONYLUREAS/

...IN MAN APPROX ONE-THIRD OF THE EXCRETED DOSE IS REPRESENTED BY THE N-ACETYLATED METABOLITE. LARGE SPECIES VARIATIONS HAVE BEEN DETECTED; THE RABBIT PRODUCES SIGNIFICANT AMT...WHILE MONKEY & DOGS ARE LOW OR VERY LOW ACETYLATORS & MAN OCCUPIES AN INTERMEDIATE POSITION.|THEY ARE HYDROXYLATED IN THE LIVER TO ACTIVE & INACTIVE PRODUCTS WHICH ARE ALMOST TOTALLY EXCRETED IN THE URINE. /SULFONYLUREAS/

SULFONYLUREAS STIMULATE ISLET TISSUE TO SECRETE INSULIN. ... SULFONYLUREAS CAUSE DEGRANULATION OF THE BETA CELLS, A PHENOMENON ASSOCIATED WITH INCR RATE OF SECRETION OF INSULIN. ...THEY ARE EFFECTIVE IN INSULIN-INDEPENDENT DIABETIC PATIENTS IN WHOM THE PANCREAS RETAINS THE CAPACITY TO SECRETE INSULIN. /SULFONYLUREAS/

FOURTEEN PT TREATED WITH CARBUTAMIDE HAD TRANSIENT HEMIPARESIS. 4 HAD IRREVERSIBLE NEUROLOGIC DEFECTS, & 5 EXPIRED AFTER HYPOGLYCEMIC COMA. NEARLY 70 OF THE EPISODES OCCURRED WITHIN THE FIRST 15 DAYS OF THE SULFONYLUREA TREATMENT.

Aminophenurobutane

Benzenesulfonamide, 4-amino-N-[(butylamino)carbonyl]-: INACTIVE

PHARMACEUTICAL COMPOUNDS TO BE DETERMINED ARE OXIDIZED BY CERIUM(IV). THE CONCENTRATION OF CE(III) FORMED IS MEASURED SPECTROFLUORIMETRICALLY.

A HIGH PRESSURE LIQUID CHROMATOGRAPHIC METHOD IS DESCRIBED FOR DETERMINING GLIBENCLAMIDE IN SERUM. THIS METHOD IS SUITABLE FOR CARBUTAMIDE.|GC PROCEDURE FOR DETERMINING ANTIDIABETIC DRUGS IN THE BLOOD IS DESCRIBED. CARBUTAMIDE WAS ONE OF THE FIVE IDENTIFIED USING THIS METHOD.